Logotype for Immunovant Inc

Immunovant (IMVT) Q2 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Immunovant Inc

Q2 2027 earnings summary

9 Nov, 2026

Executive summary

  • Development focus shifted fully to IMVT-1402 after batoclimab was discontinued in April 2026; no product revenue has been generated.

  • IMVT-1402 600 mg met the Week 28 primary endpoint in difficult-to-treat RA; $722.3M in cash was expected to fund the current plan through a potential Graves’ disease launch.

Financial highlights

  • Q2 operating expenses were $104.2M vs. $131.8M YoY; net loss was $97.2M vs. $126.5M, and loss per share was $0.47 vs. $0.73.

  • Q2 R&D was $85.0M vs. $114.2M YoY, reflecting batoclimab wind-down and manufacturing-cost timing; G&A rose to $19.1M from $17.5M, partly due to pre-commercial investment.

  • H1 operating expenses were $264.5M vs. $259.0M; net loss was $250.5M vs. $247.1M, and loss per share was $1.22 vs. $1.43.

  • H1 R&D was $227.6M vs. $215.4M, primarily reflecting IMVT-1402 trials and manufacturing; G&A was $36.8M vs. $43.5M.

  • Cash and cash equivalents were $722.3M at September 30, 2026, down from $902.1M at March 31; H1 operating cash use was $207.6M.

Outlook and guidance

  • Current cash was expected to fund the operating plan through potential IMVT-1402 launch in Graves’ disease; potential expansion after D2T RA results was not included, with updated runway guidance expected if plans are finalized.

  • Top-line results are expected in 2027 for Graves’ disease and myasthenia gravis, and in 2028 for CIDP.

  • FDA discussions on the D2T RA registrational path were planned for later in 2026; trial design and development plans remain subject to regulatory alignment.

  • Advancement in Sjögren’s beyond the ongoing, fully enrolled Phase 2 trial is considered unlikely.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Immunovant